Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebokitug in NASH (SPLASH)
NCT05824156Phase 2Completed
- Sponsor
- Chemomab Therapeutics
- Start
- Feb 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing 5 mg/kg CM-101 with Placebo (2 arms). Primary endpoint: Treatment emergent adverse events at 14 weeks. Started Feb 2021; status: completed.
02
Drugs
nebokitug
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05824156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824156.